Tags

Type your tag names separated by a space and hit enter

Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
Arterioscler Thromb Vasc Biol. 2008 Sep; 28(9):1672-8.AT

Abstract

OBJECTIVE

Extended-release niacin effectively lowers plasma TG levels and raises plasma high-density lipoprotein (HDL) cholesterol levels, but the mechanisms responsible for these effects are unclear.

METHODS AND RESULTS

We examined the effects of extended-release niacin (2 g/d) and extended-release niacin (2 g/d) plus lovastatin (40 mg/d), relative to placebo, on the kinetics of apolipoprotein (apo) A-I and apoA-II in HDL, apoB-100 in TG-rich lipoproteins (TRL), intermediate-density lipoproteins (IDL) and low-density lipoproteins (LDL), and apoB-48 in TRL in 5 men with combined hyperlipidemia. Niacin significantly increased HDL cholesterol and apoA-I concentrations, associated with a significant increase in apoA-I production rate (PR) and no change in fractional catabolic rate (FCR). Plasma TRL apoB-100 levels were significantly lowered by niacin, accompanied by a trend toward an increase in FCR and no change in PR. Niacin treatment significantly increased TRL apoB-48 FCR but had no effect on apoB-48 PR. No effects of niacin on concentrations or kinetic parameters of IDL and LDL apoB-100 and HDL apoA-II were noted. The addition of lovastatin to niacin promoted a lowering in LDL apoB-100 attributable to increased LDL apoB-100 FCR.

CONCLUSIONS

Niacin treatment was associated with significant increases in HDL apoA-I concentrations and production, as well as enhanced clearance of TRL apoB-100 and apoB-48.

Authors+Show Affiliations

Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA. stefania.lamon-fava@tufts.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

18566298

Citation

Lamon-Fava, Stefania, et al. "Extended-release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-containing Lipoproteins." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 9, 2008, pp. 1672-8.
Lamon-Fava S, Diffenderfer MR, Barrett PH, et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28(9):1672-8.
Lamon-Fava, S., Diffenderfer, M. R., Barrett, P. H., Buchsbaum, A., Nyaku, M., Horvath, K. V., Asztalos, B. F., Otokozawa, S., Ai, M., Matthan, N. R., Lichtenstein, A. H., Dolnikowski, G. G., & Schaefer, E. J. (2008). Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(9), 1672-8. https://doi.org/10.1161/ATVBAHA.108.164541
Lamon-Fava S, et al. Extended-release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-containing Lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28(9):1672-8. PubMed PMID: 18566298.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. AU - Lamon-Fava,Stefania, AU - Diffenderfer,Margaret R, AU - Barrett,P Hugh R, AU - Buchsbaum,Aaron, AU - Nyaku,Mawuli, AU - Horvath,Katalin V, AU - Asztalos,Bela F, AU - Otokozawa,Seiko, AU - Ai,Masumi, AU - Matthan,Nirupa R, AU - Lichtenstein,Alice H, AU - Dolnikowski,Gregory G, AU - Schaefer,Ernst J, Y1 - 2008/06/19/ PY - 2008/6/21/pubmed PY - 2008/9/17/medline PY - 2008/6/21/entrez SP - 1672 EP - 8 JF - Arteriosclerosis, thrombosis, and vascular biology JO - Arterioscler Thromb Vasc Biol VL - 28 IS - 9 N2 - OBJECTIVE: Extended-release niacin effectively lowers plasma TG levels and raises plasma high-density lipoprotein (HDL) cholesterol levels, but the mechanisms responsible for these effects are unclear. METHODS AND RESULTS: We examined the effects of extended-release niacin (2 g/d) and extended-release niacin (2 g/d) plus lovastatin (40 mg/d), relative to placebo, on the kinetics of apolipoprotein (apo) A-I and apoA-II in HDL, apoB-100 in TG-rich lipoproteins (TRL), intermediate-density lipoproteins (IDL) and low-density lipoproteins (LDL), and apoB-48 in TRL in 5 men with combined hyperlipidemia. Niacin significantly increased HDL cholesterol and apoA-I concentrations, associated with a significant increase in apoA-I production rate (PR) and no change in fractional catabolic rate (FCR). Plasma TRL apoB-100 levels were significantly lowered by niacin, accompanied by a trend toward an increase in FCR and no change in PR. Niacin treatment significantly increased TRL apoB-48 FCR but had no effect on apoB-48 PR. No effects of niacin on concentrations or kinetic parameters of IDL and LDL apoB-100 and HDL apoA-II were noted. The addition of lovastatin to niacin promoted a lowering in LDL apoB-100 attributable to increased LDL apoB-100 FCR. CONCLUSIONS: Niacin treatment was associated with significant increases in HDL apoA-I concentrations and production, as well as enhanced clearance of TRL apoB-100 and apoB-48. SN - 1524-4636 UR - https://www.unboundmedicine.com/medline/citation/18566298/Extended_release_niacin_alters_the_metabolism_of_plasma_apolipoprotein__Apo__A_I_and_ApoB_containing_lipoproteins_ L2 - https://www.ahajournals.org/doi/10.1161/ATVBAHA.108.164541?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -